Marathon Trading Investment Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-4,000
Closed -$203K – 312
2026
Q1
$203K Sell
4,000
-11,200
-74% -$523K 0.01% 181
2025
Q4
$448K Buy
+15,200
New +$413K 0.01% 190
2025
Q2
– Sell
-4,800
Closed -$136K – 339
2025
Q1
$136K Buy
+4,800
New +$170K 0.02% 260
2024
Q4
– Sell
-1,500
Closed -$100K – 349
2024
Q3
$100K Sell
1,500
-4,500
-75% -$413K 0.01% 225
2024
Q2
$713K Buy
6,000
+300
+5% +$38K 0.05% 121
2024
Q1
$607K Hold
5,700
– – 0.05% 142
2023
Q4
$567K Buy
5,700
+1,500
+36% +$126K 0.03% 202
2023
Q3
$434K Buy
4,200
+1,200
+40% +$134K 0.04% 163
2023
Q2
$365K Buy
+3,000
New +$400K 0.03% 142
2023
Q1
– Sell
-5,500
Closed -$988K – 307
2022
Q4
$988K Buy
5,500
+1,700
+45% +$278K 0.12% 100
2022
Q3
$449K Buy
3,800
+2,400
+171% +$364K 0.04% 161
2022
Q2
$200K Sell
1,400
-900
-39% -$129K 0.02% 220
2022
Q1
$396K Buy
+2,300
New +$387K 0.03% 191
2020
Q4
– Sell
-4,800
Closed -$340K – 376
2020
Q3
$340K Buy
+4,800
New +$335K 0.03% 214

Other funds holding MRNA

Marathon Trading Investment Management's MRNA Position: Q2 2026 in Review

Marathon Trading Investment Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 203 shares — an estimated $10.3K sold.

Marathon Trading Investment Management first reported a position in MRNA in Q4 2020 and held it in 11 quarters. The position peaked at $2.84M in Q4 2023. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Marathon Trading Investment Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Marathon Trading Investment Management sold 203 Moderna shares in Q2 2026, an estimated $10.3K.
  • Marathon Trading Investment Management first reported a position in Moderna in Q4 2020 and held it in 11 quarters.
  • Marathon Trading Investment Management's Moderna position peaked at $2.84M in Q4 2023.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Marathon Trading Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.